ViaLase, the California developer of laser-based glaucoma treatment, has announced that the first patient has been treated in its US Investigational Device Exemption (IDE) clinical trial. The trial is ...
ALISO VIEJO, Calif.--(BUSINESS WIRE)--ViaLase, Inc., a clinical-stage medical technology company pioneering incision-free, laser-based solutions for glaucoma, today announced that the first patient ...
PER-001 demonstrated a favorable safety and tolerability profile in diabetic retinopathy and glaucoma SAN FRANCISCO, June 24, 2025 /PRNewswire/ -- Perfuse Therapeutics, Inc., a biopharmaceutical ...
Initial case conducted by Dr. David Godfrey at Glaucoma Associates of Texas The IDE study will evaluate the safety and effectiveness of the company's Calibreye™ Titratable Glaucoma Therapy™ (TGT) ...
SAN FRANCISCO, June 24, 2025 /PRNewswire/ -- Perfuse Therapeutics, Inc., a biopharmaceutical company pioneering transformational therapies to treat ischemia-induced ocular diseases, today announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results